Docetaxel Dosing in Lung Cancer Treatment
Author Information
Author(s): Fr Brunsvig Paal, Andersen Anders, Aamdal Steinar, Kristensen Vessela, Olsen Harald
Primary Institution: Rikshospitalet-Radiumhospitalet Medical Centre
Hypothesis
The pharmacokinetics and radiosensitizing efficacy of weekly 20 mg/m2 docetaxel has not been well characterized compared to a 3-weekly 100 mg/m2 regimen.
Conclusion
Weekly docetaxel at 20 mg/m2 can maintain plasma concentrations that may support its use as a radiosensitizer for up to a week.
Supporting Evidence
- The study demonstrated that docetaxel plasma levels can be maintained above 1 nM for 72 hours after administration.
- Median docetaxel plasma levels of 3 nM were observed 72 hours after a dose of 20 mg/m2.
- The pharmacokinetics of docetaxel showed significant inter-individual variability.
Takeaway
This study looked at how a lower dose of docetaxel can still be effective in treating lung cancer when given weekly, especially when combined with radiation.
Methodology
The study involved 34 patients with NSCLC, comparing pharmacokinetics of 20 mg/m2 weekly docetaxel with 100 mg/m2 every 3 weeks.
Limitations
The study had a small sample size and was descriptive in nature without planned statistical comparisons.
Participant Demographics
{"total_patients":34,"male":18,"female":16,"median_age":63,"age_range":"45-81"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website